Revance Therapeutics Inc expected to post a loss of 78 cents a share - Earnings Preview

Revance Therapeutics

05/08/2023 03:03

* Revance Therapeutics Inc  RVNC.OQ   RVNC.O  is expected
to show
a rise in quarterly revenue when it reports  results on August
8. 
    * The Nashville Tennessee-based  company is expected to
report  a
108.1% increase in revenue to $59.039 million from $28.37
million a year ago, according to the mean estimate from 11
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Revance
Therapeutics Inc
is for a loss of 78 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Revance
Therapeutics Inc is $40​, above​ its last closing price
of $22.75. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.74       -0.70      -0.74     Missed  -5.9
 Dec. 31 2023  -1.05       -0.95      -0.95     Met     -0.1
 Sep. 30 2022  -0.91       -0.89      -1.17     Missed  -30.8​
 Jun. 30 2022  -0.89       -0.86      -0.88     Missed  -2.3
 ​​Mar.        -0.93       -0.83      -0.94     Missed  -12.6
 31 2022                                                
 Dec. 31 2021  -0.95       -1.00      -0.93     Beat    6.6​
 Sep. 30 2021  -1.15       -1.15      -1.10     Beat    4.5
 Jun. 30 2021  -1.09       -1.05      -1.07     Missed  -1.6
 This summary was machine generated August 5 at 02:03 GMT.  All
figures in US dollars  unless otherwise stated